Prophylactic urethral stenting with memokath® 028SW in prostate cancer patients undergoing prostate 125I seed implants: Phase I/II study

Journal of Contemporary Brachytherapy

Volumn 3, Issue 1, 2011, Pages 18-22

  Chao, Samuel T ^a   Angermeier, Kenneth ^b   Klein, Eric A ^b   Reddy, Chandana A ^a   Ulchaker, James C ^b   Stephenson, Andrew ^b   Campbell, Steven ^b   Ciezki, Jay P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Prostate brachytherapy; Prostate cancer; Urethral obstruction; Urethral stent

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BELLADONNA ALKALOID; DARIFENACIN; IODINE 125; OPIATE; OXYBUTYNIN; PHENAZOPYRIDINE; TROSPIUM CHLORIDE;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BLADDER DISCOMFORT; BLADDER SPASM; BRACHYTHERAPY; BURNING SENSATION; CANCER SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; DEVICE REMOVAL; FEASIBILITY STUDY; FOLLOW UP; HEMATURIA; HUMAN; INTERMITTENT CATHETERIZATION; MALE; ORGAN SIZE; PATIENT ASSESSMENT; PATIENT PREFERENCE; PATIENT SAFETY; PROSTATE ADENOCARCINOMA; PROSTATE VOLUME; RECTUM DISEASE; RECTUM SPASM; SCORING SYSTEM; TELEPHONE; TREATMENT DURATION; URETER STENT; URINARY BURNING; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE;

EID: 79953672958     PISSN: 1689832X     EISSN: None     Source Type: Journal    
DOI: 10.5114/jcb.2011.21038     Document Type: Article

References (21)

1. Ragde H, Blasko J, Grimm P et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997; 80: 442-453. (Pubitemid 27323414)
2. Ragde H, Korb L, Elgamal A et al. Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000; 89: 135-141. (Pubitemid 30451283)
3. Blasko J, Ragde H, Grimm P. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 1991; 137: 113-118.
4. Kleinberg L, Wallner K, Roy J et al. Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 1994; 28: 985-990. (Pubitemid 24099881)
5. Terk M, Stock R, Stone N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998; 160: 1379-1382. (Pubitemid 29480520)
6. Benoit R, Naslund M, Cohen J. A comparison of complications between ultrasound-guided prostate brachytherapy and open prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 47: 909-913. (Pubitemid 30345587)
7. Lee N, Wuu C, Brody R et al. Factors predicting for post-implantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1457-1460.
8. Kaplan SA. Alpha-Blocker therapy. Rev Urol 2005; Suppl 8: 34-42.
9. Bruno JF, Whittaker J, Song J et al. Molecular cloning and sequencing of cDNA encoding the human alpha 1A adrenergic receptors. Biochem Bioph Res Commun 1991; 179: 1485-1490.
10. Ramarao CS, Denker JMK, Perez DM et al. Genomic organization and expression of the human alpha 1B-adrenergic receptors. J Bio Chem 1992; 267: 21936-21945.
11. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostate hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892-900. (Pubitemid 28240845)
12. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901-906. (Pubitemid 28240846)
13. Chapple CR, Wyndaile JJ, Nordling J et al. Tamsulosin, the first prostate-selective alpha1A adrenoreceptors antagonist: A metaanalysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-167.
14. Schilman CC, Cortvriend J, Jonas U et al. Tamsulosin, the first prostate-selective alpha1A adrenoreceptors antagonist: Analysis of multinational, multicenter, open-label study assessing the long term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 145-154. (Pubitemid 26059418)
15. Elshaikh MA, Ulchaker J, Reddy CA et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125-I seed implants for prostate carcinoma: final report of double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 2005; 62: 164-169. (Pubitemid 40591938)
16. Perry MJ, Roodhouse AJ, Gidlow AB et al. Thermo-expandable intraprostatic stents in bladder outlet obstruction: an 8-year study. BJU Int 2002; 90: 216-223. (Pubitemid 34989066)
17. Nag S, Beyer D, Friedland J et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789-799. (Pubitemid 29284127)
18. Nag S, Bice W, DeWyngaert J et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy post-implant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000; 46: 221-230. (Pubitemid 30021503)
19. Konety BR, Phelan MW, O'Donnell WF et al. UroLume stent placement for the treatment of post-brachytherapy bladder outlet obstruction. Urology 2000; 55: 721-724.
20. Henderson A, Laing RW, Langley SE. A Spanner™ in the works; the use of a new temporary urethral stent to relieve bladder outflow obstruction after prostate brachytherapy. Brachytherapy 2002; 1: 212-218.
21. Elshaikh MA, Angermeier K, Ulchaker JC et al. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology 2003; 61: 152-155. (Pubitemid 36151732)